| 1. |
Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study. （口頭発表，一般） 2022/12/12
|
| 2. |
Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma. （ポスター，一般） 2022/12/10
|
| 3. |
Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study). （ポスター，一般） 2022/12/10
|
| 4. |
P-IIb study of oral HDAC inhibitor HBI-8000 in relapsed or refractory adult T-cell leukemia/lymphoma, （口頭発表，一般） 2022/11/06
|
| 5. |
Characteristics of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma – a supplementary analysis of JCOG0601. （ポスター，一般） 2022/06/09
|
| 6. |
Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma , （口頭発表，一般） 2021/12/11
|
| 7. |
A Phase 2b study of an oral HDAC inhibitor HBI-8000 in patients with relapsed or refractory ATL. （一般） 2021/09
|
| 8. |
A phase 2b study of an oral HDAC inhibitor HBI-8000 in patients with relapsed or refractory PTCL. （一般） 2021/09
|
| 9. |
Factors critical for the results of panel sequencing using DNA from FFPE samples in lymphoma. （一般） 2021/09
|
| 10. |
A PHASE 2B OPEN-LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HBI-8000 (TUCIDINOSTAT) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA （ポスター，一般） 2021/06
|
| 11. |
A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUCIDINOSTAT (HBI-8000) IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY ADULT T-CELL LEUKEMIA-LYMPHOMA (ATL). （ポスター，一般） 2021/06
|
| 12. |
FIRST-IN-HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS-3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS, （口頭発表，一般） 2021/06
|
| 13. |
5-Year Results Of A Phase 3 Study Of Frontline Brentuximab Vedotin + CHP Vs CHOP In Patients With CD30-Positive Peripheral T-Cell Lymphoma （一般） 2021/04
|
| 14. |
ECHELON-2 (NCT01777152) a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone vs cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results. （一般） 2021/04
|
| 15. |
The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-positive Peripheral T-Cell Lymphoma （ポスター，一般） 2020/12/05
|
| 16. |
4. 未治療多発性骨髄腫に対するMPB療法変法のランダム化第II相試験（JCOG1105最終解析）, 国内（WEB）,2020年10月10日,口演 （口頭発表，一般） 2020/10/10
|
| 17. |
5. HLAタイピングによる未治療多発性骨髄腫に対するMPB療法の毒性および腫瘍縮小効果の予測, （口頭発表，一般） 2020/10/10
|
| 18. |
濾胞辺縁帯B細胞性リンパ腫の検討, （ポスター，一般） 2020/10/10
|
| 19. |
6. 当科におけるベンダムスチン療法の検討, （抄録提出，一般） 2020/08/20
|
| 20. |
7. 当院における濾胞辺緑帯由来B細胞性リンパ腫の検討, （抄録提出，一般） 2020/08/20
|
| 21. |
FINAL ANALYSIS OF RANDOMIZED PHASE II STUDY FOR OPTIMIZING MELPHALAN, PREDNISOLONE AND BORTEZOMIB IN TRANSPLANT-INELIGIBLE UNTREATED, MULTIPLE MYELOMA: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG1105), （ポスター，一般） 2020/06/11
|
| 22. |
, リンパ形質細胞性リンパ腫（LPL）の治療開始後に骨髄抑制が遷延しMDS と診断し得た 1 例, （抄録提出，一般） 2020/03/14
|
| 23. |
リンパ形質細胞性リンパ腫（LPL）の治療開始後に骨髄抑制が遷延しMDS と診断し得た 1 例, （抄録提出，一般） 2020/03/14
|
|
5件表示
|
|
全件表示(23件)
|